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Myosin VI is an actin-based cytoskeletal motor impli-
cated in various steps of membrane trafficking. Here,
we investigated whether this myosin is crucial for
synaptic function and plasticity in neurons. We find
that myosin VI localizes at cerebellar parallel fiber
to Purkinje cell synapses and that themyosin is indis-
pensable for long-term depression of AMPA-recep-
tor-mediated synaptic signal transmission at this
synapse. Moreover, direct visualization of GluA2-
containing AMPA receptors in Purkinje cells reveals
that the myosin drives removal of AMPA receptors
from the surface of dendritic spines in an activity-
dependentmanner. Co-immunoprecipitation and su-
per-resolution microscopy indicate that specifically
the interaction of myosin VI with the clathrin adaptor
component a-adaptin is important during long-term
depression. Together, these data suggest that
myosin VI directly promotes clathrin-mediated endo-
cytosis of AMPA receptors in Purkinje cells to
mediate cerebellar long-term depression. Our results
provide insights into myosin VI function and the mo-
lecular mechanisms underlying synaptic plasticity.
INTRODUCTION
Synaptic plasticity, such as long-term potentiation (LTP) and
long-term depression (LTD), is thought to underlie learning and
memory. Amajor way in which such long-lasting changes in syn-
aptic strength are achieved is via varying the number of AMPA
receptors (AMPARs) at excitatory synapses (Choquet and Triller,
2013; Kneussel and Hausrat, 2016). Regulated AMPAR
trafficking along exo- and endocytic pathways facilitates theThis is an open access article under the CC BY-Nmodulation of synaptic receptor numbers. Notably, clathrin-
mediated endocytosis (CME) of the GluA2 subunit of AMPARs
is needed for the downregulation of synaptic AMPARs following
stimulation and thus for LTD (Man et al., 2000; Wang and Linden,
2000). Nevertheless, a complete picture of the molecular ma-
chinery that mediates LTD-related receptor trafficking is still
missing.
Myosins are actin-based cytoskeletal motor proteins, some of
which play important roles at synapses (Kneussel and Wagner,
2013; Wagner et al., 2011a). Myosin VI, a unique myosin that
moves toward the minus end of the actin filament (Spudich
and Sivaramakrishnan, 2010; Wells et al., 1999), is a candidate
for regulating postsynaptic function (Heisler et al., 2011; Kneus-
sel andWagner, 2013). It acts in various steps of membrane traf-
ficking, including CME (Buss et al., 2001; Spudich et al., 2007;
Wollscheid et al., 2016), endocytic vesicle transport (Aschen-
brenner et al., 2004), and secretion (Tomatis et al., 2013). Myosin
VI may also affect actin organization (Isaji et al., 2011; Majewski
et al., 2012; Masters et al., 2017).
In brain, myosin VI is present in complex with AMPAR subunits
GluA1 and GluA2, the scaffold proteins bSAP97 and GRIP1, as
well as the endocytic clathrin machinery (Lv et al., 2015; Oster-
weil et al., 2005; Wu et al., 2002). Both bSAP97 and GRIP1 might
provide a physical link between AMPARs andmyosin VI. bSAP97
directly interacts with the C-terminal tail of GluA1 and with the
cargo-binding domain (CBD) of the myosin VI heavy chain,
MYO6 (Wu et al., 2002). In contrast, GRIP1 directly interacts
with GluA2 and with MYO6 (Lv et al., 2015; Huganir and Nicoll,
2013). Also, the endocytic clathrin machinery is potentially
involved in bridging the myosin to AMPARs, as it interacts with
both GluA2 and a specific splice isoform of myosin VI (Man
et al., 2000; Wollscheid et al., 2016). Myosin VI is reported to
affect AMPAR trafficking in hippocampal neurons in different
ways. In absence of MYO6, CME-dependent internalization of
GluA1 following AMPAR stimulation is impaired (Osterweil
et al., 2005). Moreover, forced recruitment of myosin VI toCell Reports 28, 11–20, July 2, 2019 ª 2019 The Author(s). 11
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
AMPAR-carrying recycling endosomes leads to their transport
out of dendritic spines (Esteves da Silva et al., 2015). Finally, it
has been suggested that myosin VI, via its interaction with
bSAP97, is important for AMPAR cell surface delivery (Nash
et al., 2010).
Together, these findings raise several questions: (1) is myosin
VI required for synaptic plasticity in the form of CME-dependent
LTD of AMPAR-mediated synaptic transmission? (2) Is the
myosin also needed for activity-dependent endocytosis of
GluA2, and is it directly involved or rather acting via promoting
synaptic development or other upstream events? (3) What are
themolecular interactions by whichmyosin VI regulates synaptic
AMPAR levels in an activity-dependent manner?
Here, we address these questions by studying the cerebellum,
one of the brain regions where Myo6 is expressed (Osterweil
et al., 2005). Within the cerebellum, Purkinje cells (PCs) are the
central neuronal signal integrators and, as such, are crucial for
motor coordination, language, and social cognition (Galliano
et al., 2018; Ito, 2001; Sokolov et al., 2017). PCs provide the
sole output from the cerebellar cortex and receive excitatory
input from parallel fibers (PFs) and climbing fibers (CFs) (Ito,
2001). LTD at PF-PC synapses is mediated by CME of GluA2-
containing AMPARs and triggered by a signaling cascade
involving metabotropic glutamate receptor (mGluR1) and PKC-
dependent phosphorylation of GluA2 (Chung et al., 2003; Mat-
suda et al., 2000; Steinberg et al., 2006;Wang and Linden, 2000).
RESULTS
Myosin VI Is Present in PC Spines and Bergmann Glia
Processes
To elucidate the role of myosin VI in cerebellum, we co-immuno-
stained mouse cerebellar sections using antibodies against
MYO6 (Wollscheid et al., 2016) and calbindin-D-28K to label
PCs. MYO6 was present throughout the cerebellar cortex,
including the molecular layer (ML) (Figure 1A). As control, we
used Snell’s waltzermice (referred to asMyo6sv/sv) homozygous
for a recessive Myo6 loss-of-function allele (Avraham et al.,
1995; Deol and Green, 1966; Figure S1A). Western blot of
Myo6sv/sv cerebellar extracts confirmed the absence of full-
length MYO6 (Figure S1B). Immunostaining of Myo6sv/sv cere-
bellar sections usingMYO6 antibody verified antibody specificity
(Figure 1A). Next, we examined the ML in more detail using triple
staining for MYO6, calbindin-D-28K, and VGLUT1, a marker for
PF synaptic terminals. MYO6 was localized at PC dendritic
spines, with only marginal signal overlap at VGLUT1-positive
presynaptic terminals (Figure 1B). MYO6 also hardly overlapped
with VGLUT2, a marker for CF synaptic terminals (Figure S1C),
indicating that MYO6 is not predominantly presynaptic at PF-
and CF-PC synapses. Immunoelectron microscopy (EM)
showed that MYO6 localizes within dendritic spines of the ML
and on tubulo-vesicular clusters in perisynaptic processes of
Bergmann glia (Bg) cells that ensheathe the PC spines (Figures
1C and S1F–S1H). To independently confirm the myosin’s local-
ization, we observed Myo6sv/sv PCs expressing GFP-tagged
MYO6 either lacking (GFP-MYO6-SI) or comprising the alterna-
tively spliced large insert (GFP-MYO6-LI-SI). Both variants
were significantly enriched in spines relative to dendrite shafts12 Cell Reports 28, 11–20, July 2, 2019(Figures 1D and 1E). Moreover, MYO6 lacking the cargo-binding
domain (CBD), but not GFP alone, also was enriched in
spines (Figures 1D and 1E; GFP-MYO6DCBD, GFP). Thus,
myosin VI localizes to PC spines, and its spine accumulation is
independent of the CBD.
Acute Inhibition of Myosin VI Blocks LTD of
AMPAR-Mediated Currents at PF-PC Synapses
LTD at PF-PC synapses depends on CME of GluA2-containing
AMPARs (Wang and Linden, 2000), and myosin VI is important
for CME in several cell types, including hippocampal neurons
(Osterweil et al., 2005). Thus, we examined whether PF-PC
LTD in cerebellar slices depends on myosin VI. PF stimulation
paired with PC depolarization to induce LTD of AMPAR-medi-
ated excitatory postsynaptic currents (EPSCs) in PCs led to
robust LTD at wild-type (WT) synapses. In contrast, LTD was
significantly impaired at Myo6sv/sv PF-PC synapses (Figure 2A).
To ask whether LTD impairment is due to a dominant-negative
effect of truncated MYO6 that might still be produced from the
sv allele, we examined slices of heterozygous Myo6sv/+ mice.
However, PF-PC LTD in Myo6sv/+ slices was indistinguishable
from WT (Figure 2A), ruling out a dominant-negative effect of
sv on LTD.
We then assessed whether impaired LTD in Myo6sv/sv cere-
bellum reflects an acute requirement of myosin VI for synaptic
plasticity or whether it is an indirect consequence of a develop-
mental deficit. Visualization of PF and CF terminals did not
expose gross morphological deficits of excitatory input into
Myo6sv/sv PCs (Figures S1D and S1E). In contrast, LTD experi-
ments performed on WT cerebellar slices in the presence of
the myosin VI inhibitor 2,4,6-triiodophenol (TIP) (Heissler et al.,
2012) revealed a striking impairment of PF-PC LTD (Figure 2B).
TIP did not lead to an additional impairment of LTDwhen applied
to Myo6sv/sv slices (Figure 2C), demonstrating that the effect of
TIP on LTD is myosin VI dependent. Of note, when compared
to LTD induced in absence of DMSO, the presence of vehicle
led to stronger LTD in Myo6sv/sv, but not in WT (Figures 2A–
2C). Control experiments excluded an effect of TIP onmembrane
resistance and basal EPSC amplitudes inWT andMyo6sv/sv (Fig-
ures S2A–S2K). Moreover, paired-pulse facilitation of PF synap-
ses, a measure of presynaptic function, was not altered by TIP
(Figures S2F–S2J).
To determine whether also basal synaptic transmission is
affected in Myo6sv/sv PCs, we measured spontaneous AMPAR-
mediated miniature EPSCs (mEPSCs) from cultured PCs (Fig-
ure S2L). However, compared to WT, Myo6sv/sv PCs exhibited
comparable mEPSCs peak amplitude and inter-event interval
(Figure 2D). Moreover, we observed no deficits in terms of overall
morphology, dendrite length, and spine density of cultured
Myo6sv/sv PCs (Figures S2M–S2O). We therefore conclude that
basal synaptic transmission remains normal upon myosin deple-
tion and inhibition, whereas LTD of AMPAR-mediated synaptic
transmission at PF-PC synapses acutely requires myosin VI.
Myosin VI Mediates Removal of SEP-GluA2 from the
Spine Surface of Cultured PCs upon cLTD
Because removal of synaptic GluA2-containing AMPARs leads
to PF-PC LTD (Huganir and Nicoll, 2013), the requirement of
Figure 1. Myosin VI Sub-cellular Localization in the
Cerebellum
(A) Confocal images of cerebellar sections from littermate
control (wild-type) and Myo6sv/sv mice, immunofluorescently
labeled with aMYO6 (SP1296) and acalbindin-D-28K anti-
bodies. Scale bar, 50 mm.
(B) Confocal images of WT cerebellar molecular layer im-
munofluorescently labeled with aMYO6 (SP1296), acalbin-
din-D-28K, and aVGLUT1 antibodies. Scale bar, 5 mm. Bot-
tom panels: magnifications of boxed regions in aMYO6
acalbindin-D-28K panel are shown. White ovals: examples of
spines overlapped by MYO6 are shown.
(C) EM images of cerebellar molecular layer sections labeled
with aMYO6 (SP1295) and 10 nm gold coupled secondary
antibodies (green arrowheads). Bg, Bergmann glia; Po,
postsynapse; Pr, presynapse. Scale bar, 250 nm.
(D) Spinning disk confocal images of cultured live Myo6sv/sv
PCs co-transfected with PC-specific expression plasmids
pL7-FusionRed (volume marker) and pL7-mGFP-Myo6-SI,
pL7-mGFP-Myo6-LI-SI, or pL7-mGFP-Myo6DCBD. Bottom
panels: magnifications of top panels are shown. Scale bar,
20 mm.
(E) Quantification of GFP fluorescence intensity enrichment in
spines relative to dendrite shafts of the PCs described in (D).
WT PCs expressing GFP and FusionRed were analyzed as
negative control. Magenta: median ± 95% confidence inter-
val (CI); data points represent analyzed PCs. One sample t
test against 1.0-fold enrichment shows significant difference
for each GFP-MYO6 construct (p < 0.0001), but not for GFP
alone (p = 0.3127).
See also Figure S1.
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Figure 2. Acute Inhibition of Myosin VI Blocks LTD of
AMPAR-Mediated Currents at PF-PC Synapses
(A) Amplitudes of PF-evoked EPSCs in PCs of acuteMyo6sv/sv,
Myo6sv/+, and WT cerebellar slices. (Left graph) Means of
relative EPSC amplitudes ± SEMbefore and after stimulation of
PFs paired with depolarization of the PC to 0 mV are shown
(903 at 1 Hz at t = 0 min). (Right graph) Post-induction EPSC
amplitudes at 50–60 min normalized to10 to 0 min relative to
paired stimulation are shown (magenta: mean ± SEM; data
points represent analyzed PCs). Paired stimulation led to
robust LTDof EPSCs inWT (n = 12) and heterozygousMyo6sv/+
PCs (n = 7). Significantly less LTD was observed in Myo6sv/sv
PCs (n = 9); p = 0.037, one-way ANOVA; WT versusMyo6sv/sv:
p = 0.0269;Myo6sv/+ versusMyo6sv/sv: p = 0.007; Tukey’s post
hoc test.
(B) Amplitudes of PF-evoked EPSCs in PCs of WT cerebellar
slices exposed to TIP or vehicle. Significantly less LTD of EPSC
amplitudes in presence of 10 mM TIP (n = 8) compared to
vehicle are shown (0.01%DMSO; n = 9); p = 0.004, Student’s t
test.
(C) Amplitudes of PF-evoked EPSCs in PCs of Myo6sv/sv
cerebellar slices exposed to TIP or vehicle. No significant dif-
ference in LTD in Myo6sv/sv PCs exposed to 10 mM TIP (n = 8)
compared to vehicle is shown (0.01% DMSO; n = 7); p = 0.52;
Student’s t test.
(D) Peak amplitudes and inter-event interval of AMPAR-medi-
ated mEPSCs in cultured Myo6sv/sv, Myo6sv/+, and WT PCs.
Magenta: median ± 95% CI; data points represent analyzed
PCs. No significant differences between genotypes formEPSC
peak amplitudes (p= 0.3772) and inter-event interval are shown
(p = 0.8916); Kruskal-Wallis tests.
See also Figure S2.
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Figure 3. Myosin VI Mediates Removal of SEP-GluA2 from the Spine Surface of Cultured PCs upon cLTD
(A–C) Antibody uptake assay. Confocal images ofWT (A) andMyo6sv/sv (B) hippocampal neurons, incubated with aGluA2 antibody and treatedwith 100 mMAMPA
for 10 min (+AMPA) or mock-treated (AMPA) are shown. Shown are surface GluA2 (sGluA2) and internalized GluA2 (iGluA2). Scale bars, 20 mm. Graph in (C)
depicts internalization index; magenta: median ± 95% CI; data points represent analyzed cells. p = 0.0031, Kruskal-Wallis test; WTAMPA versus WT+AMPA,
p = 0.0088; Myo6sv/svAMPA versus Myo6sv/sv+AMPA, p = 0.2283; WTAMPA versus Myo6sv/svAMPA: p = 0.2461; WT+AMPA versus Myo6sv/sv+AMPA:
p = 0.0074; Dunn‘s multiple comparisons test.
(D and E) Spinning disk confocal images of live WT and Myo6sv/sv PCs transfected with pL7-mCherry (volume) and pL7-SEP-GluA1 (D) or pL7-SEP-GluA2 (E).
Bottom panels: magnification of boxed regions is shown. Scale bars, 20 mm (top panels) and 2 mm (bottom panels).
(F) SEP-GluA2 fluorescence on PC spines diminishes after DHPG and AMPA treatment. (Top row, left panel) Spinning disk confocal image of SEP-GluA2 in a WT
PC is shown. Scale bar, 10 mm.Cultures were exposed to 100 mMDHPG and 100 mMAMPA for 15min. Panels with false-color-coded images depict boxed region
at the indicated time points before and after start of DHPG and AMPA treatment.
(legend continued on next page)
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myosin VI for PF-PC LTD suggests that the myosin is important
for endocytic uptake of GluA2 following induction of plasticity.
Therefore, we measured GluA2 internalization in cultured hippo-
campal neurons (Figures 3A–3C). Under basal conditions, the
GluA2 internalization index was similar in Myo6sv/sv and WT
neurons, indicating that GluA2 endocytosis is not impaired.
However, following stimulation of AMPAR CME using AMPA
(Man et al., 2000), the GluA2 internalization index increased
significantly in WT, but not in Myo6sv/sv cells. Thus, myosin VI
is important specifically for activity-induced endocytosis of
GluA2-containing AMPARs, but not for their endocytosis under
basal conditions.
To test whether myosin VI regulates AMPAR localization in
PCs, we visualized surface-exposed AMPARs via super-ecliptic
pHluorin (SEP)-tagged GluA1 and GluA2 (Kopec et al., 2006).
Compared to volume marker, both SEP-GluA1 and SEP-GluA2
fluorescence was enriched at spines of cultured WT and
Myo6sv/sv PCs (Figures 3D and 3E), indicating that the myosin
is not essential for accumulating surface-exposed AMPARs on
PC spines. Notably, fluorescence recovery after photobleaching
(FRAP) measurements indicated increased mobility of GluA1-
containing AMPARs on the spine surface of Myo6sv/sv PCs (Fig-
ures S3A–S3C).
Exposure to the mGluR1/5 agonist (S)-3,5-dihydroxyphenyl-
glycine (DHPG) and glutamate leads to LTD of AMPAR-mediated
mEPSCs in PCs of dissociated cultures (Smith-Hicks et al.,
2010). Thus, we similarly exposed SEP-GluA2-expressing,
cultured PCs to DHPG and AMPA to determine whether myosin
VI is needed for surface GluA2 downregulation at spines
following plasticity-inducing stimulation (Figures 3F–3H). Appli-
cation of DHPG and AMPA for 15 min led to the depression of
SEP-GluA2 spine signal of WT PCs as monitored 75 min after
treatment start, indicating a persistent downregulation of SEP-
GluA2 at the spine surface (Figures 3F and 3G). In contrast, the
same stimulation led to significantly less depression of SEP-
GluA2 signal on Myo6sv/sv PC spines (Figure 3G). As in case of
PF-PC LTD, SEP-GluA2 downregulation at the spine surface of
heterozygous Myo6sv/+ PCs did not significantly differ from WT
(Figure 3G), ruling out that the SEP-GluA2 downregulation deficit
is due to a dominant-negative effect of sv. Because PCs were
co-cultured with untransfected WT cerebellar cells, this assay
only reveals phenotypes that are likely PC intrinsic (i.e., not sup-
pressed by the presence of WT cells). We conclude that GluA2
removal from the surface of PC spines, following chemically
induced LTD (cLTD) stimulation, depends on myosin VI.
The impairment in SEP-GluA2 removal inMyo6sv/sv PCs could
be an indirect consequence of a deficit in synaptic or neuronal
development. To directly test this, we acutely applied themyosin
VI inhibitor TIP during AMPA and DHPG treatment. Compared to
vehicle, TIP significantly impaired SEP-GluA2 downregulation at(G) WT,Myo6sv/+, andMyo6sv/sv PCs expressing SEP-GluA2 were exposed to DH
AMPA and 10 mM TIP for 15 min. Depicted is post-induction SEP-GluA2 fluoresc
before treatment start. Magenta: median ± 95% CI; data points represent analyz
versus Myo6sv/sv: p = 0.0234; Myo6sv/sv versus Myo6sv/sv+TIP: p > 0.9999; Dunn‘
(H) WT PCs expressing SEP-GluA2 were exposed to DHPG and AMPA and 10 mM
fluorescence on spines as in (G). Magenta: median ± 95% CI; data points repres
See also Figure S3.
16 Cell Reports 28, 11–20, July 2, 2019the spine surface of WT PCs (Figure 3H). Notably, this effect de-
pends onmyosin VI, as TIP did not significantly affect SEP-GluA2
removal inMyo6sv/sv PCs (Figure 3G). Therefore, acute inhibition
ofmyosin VI disrupts removal of GluA2-containing AMPARs from
the PC spine surface following cLTD induction.
Interaction of Myosin VI with GluA2 and a-Adaptin
Increases during cLTD
We next examined the underlying mechanism by which myosin
VI promotes LTD. Enrichment and turnover of filamentous actin
in spines was normal inMyo6sv/sv PCs (Figures S4A–S4C), sug-
gesting that the LTD impairment is not due to an aberrant actin
cytoskeleton. We then performed a quantitative co-immuno-
precipitation (coIP) assay to determine whether neuronal stim-
ulation changes the molecular interactions of myosin VI (Fig-
ures 4A and 4B). Toward this end, acute cerebellar slices
were exposed to AMPA and DHPG for 15 min to induce
cLTD, followed by immunoprecipitation of MYO6. The amount
of GluA2 bound to MYO6 significantly increased 30 and
60 min after start of AMPA and DHPG treatment, compared
to basal conditions (Figures 4A and 4B). Importantly, this indi-
cates that the myosin acts at the level of AMPARs during
cLTD, not merely in an upstream signaling cascade. Candi-
dates for bridging myosin VI to AMPARs include bSAP97,
GRIP1, and the clathrin machinery. To dissect which of these
interactions is most relevant for LTD, their ability to coIP with
MYO6 was assessed. We used a-adaptin, a component of
the AP-2 clathrin adaptor complex, as a specific marker for
the endocytic clathrin machinery (Canagarajah et al., 2013).
Strikingly, the amount of a-adaptin that coIPs withMYO6 signif-
icantly increased 30 and 60 min after the start of AMPA and
DHPG treatment (Figures 4A and 4B). In contrast, the amount
of GRIP1 or bSAP97 did not increase but showed a significant
decrease in case of bSAP97 at 60min after cLTD induction (Fig-
ures 4A and 4B). Therefore, our data suggest an important role
specifically for the interaction of myosin VI with GluA2-contain-
ing AMPARs and the CME machinery during LTD.
To examine whether myosin VI-a-adaptin interactions take
place within PCs, we employed super-resolution microscopy
of cultured PCs expressing GFP-tagged MYO6. Analysis of co-
localization between a-adaptin and the GFP-MYO6-LI-SI splice
isoform revealed significantly increased overlap in PCs following
cLTD stimulation (Figures 4C and 4D). MYO6-LI-SI comprises
the alternatively spliced large insert (LI), which enables MYO6
to interact with the CME machinery. Conversely, MYO6 lacking
LI does not bind clathrin (Wollscheid et al., 2016). Therefore, to
test whether the increase in myosin VI-a-adaptin co-localization
depends on the myosin’s ability to bind the CME machinery, we
analyzed cells expressingGFP-MYO6-SI, lacking LI. No increase
in co-localization of a-adaptin was observed for this splicePG and AMPA as in (F). In addition,Myo6sv/sv PCs were exposed to DHPG and
ence on spines at 75 min after treatment start, normalized to values at 10 min
ed PCs. p = 0.0012, Kruskal-Wallis test; WT versus Myo6sv/+: p = 0.5793; WT
s multiple comparisons test.
TIP or vehicle (0.1%DMSO) for 15 min. Depicted is post-induction SEP-GluA2
ent analyzed PCs; p = 0.0027; Mann-Whitney test.
Figure 4. Interaction of Myosin VI with GluA2 and a-Adaptin Increases during cLTD
(A and B)MYO6 immunoprecipitation from acute cerebellar slices before and 30 and 60min after cLTD induction (DHPG and AMPA, 100 mMeach, for 15min). The
amount of GluA2, a-adaptin, GRIP1, and SAP97 that coIPswithMYO6was determined bywestern blot analysis (A); control: non-immune immunoglobulin G (IgG).
n = 4 experiments. Graphs in (B) depict quantification of coIP/MYO6 binding ratios for the indicated proteins before and 30 and 60 min after cLTD induction.
Magenta: mean ± SEM; data points represent experiments. GluA2: p = 0.0001, p = 0.0045, p = 0.0001; a-adaptin: p < 0.0001, p < 0.0001, p < 0.0001; GRIP1:
p = 0.1975, p = 0.8445, p = 0.1882; SAP97: p = 0.0286, p = 0.2056, p = 0.0234 (one-way ANOVA; Tukey’s multiple comparisons tests before versus 30 min and
before versus 60 min, respectively).
(C and D) Cultured PCs transfected with pL7-mGFP-Myo6-LI-SI or pL7-mGFP-Myo6-SI were exposed to DHPG and AMPA (100 mM each) for 15 min (cLTD) or
mock-treated (control), fixed 30 min post treatment start, and stained using aGFP nanobodies and a-adaptin antibodies.
(C) Super-resolution (stimulated emission depletion [STED]) microscopy images of PCs; white indicates overlap. Scale bars, 10 mm (left panels) and 2 mm
(right panels).
(D) Quantification of co-localization (Pearson’s correlation coefficient) of a-adaptin with MYO6-LI-SI or MYO6-SI, measured from STED images. Magenta: mean
± SEM; data points represent analyzed PCs. p < 0.0001, one-way ANOVA; MYO6-LI-SI control versus MYO6-LI-SI cLTD: p = 0.0106; MYO6-LI-SI control versus
MYO6-SI control: p = 0.5930; MYO6-SI control versus MYO6-SI cLTD: p = 0.6279; MYO6-LI-SI cLTD versus MYO6-SI cLTD: p < 0.0001; Sidak’s multiple
comparisons test.
See also Figure S4.isoform following cLTD induction (Figures 4C and 4D). Thus, the
increased myosin VI-a-adaptin co-localization following cLTD
depends on the myosin’s ability to bind to the CME machinery.
DISCUSSION
Here, we reveal that LTD of AMPAR-mediated synaptic trans-
mission at cerebellar PF-PC synapses requires the unique
actin-based cytoskeletal motor myosin VI. Moreover, we show
that the myosin is acutely required for PF-PC LTD and directly
involved in activity-dependent CME of GluA2-containing
AMPARs in PCs. This defines myosin VI as a critical player of
the postsynaptic machinery that mediates plasticity-relatedneurotransmitter receptor trafficking. Although presynaptic roles
for myosin VI have been described (Hayashida et al., 2015; Yano
et al., 2006), our findings did not hint on a presynaptic deficit as
the origin of the impaired LTD at PF-PC synapses.
Myosin VI is known to regulate distinct membrane trafficking
steps, including exo- and endocytosis. This multi-functionality
is made possible, in part, by the ability of myosin VI to bind spe-
cific cargo adaptors (Tumbarello et al., 2013). bSAP97, GRIP1,
and clathrin-AP-2 are known to interact with both myosin VI
and AMPARs (Lv et al., 2015; Wollscheid et al., 2016; Wu
et al., 2002) and thus might serve as myosin-cargo adaptors in
AMPAR trafficking. In particular, it has been proposed that
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targeting (Nash et al., 2010). Indeed, the reduction of this interac-
tion after cLTD induction suggests a role for it under basal
activity. Nonetheless, we found that myosin VI does not signifi-
cantly affect synaptic AMPAR levels in PCs under basal activity.
GRIP1 is involved in dendritic transport of GluA2-containing
AMPARs and their synaptic targeting (Huganir and Nicoll,
2013; Heisler et al., 2014). Because GRIP1 and its homolog
GRIP2 are required for PF-PC LTD (Takamiya et al., 2008), a
MYO6-GRIP1 complex might contribute to LTD, even though
we did not detect a significant change in complex formation
upon cLTD stimulation. In contrast, the same stimulation led to
a clear increase of MYO6 interactions with GluA2 and the AP-2
component a-adaptin. AP-2 is specifically required for CME,
but not other clathrin-mediated trafficking steps, and it binds
to GluA2 (Lee et al., 2002; McMahon and Boucrot, 2011).
We made use of the fact that alternative splicing of the myosin
VI heavy chain regulates the interaction with the clathrin machin-
ery, including AP-2 (Wollscheid et al., 2016). Two sites in MYO6
are subject to alternative splicing (Buss et al., 2001). Presence of
the small insert (SI) in the CBD allows the myosin to be recruited
to secretory granules and to regulate their cortical tethering
(Tomatis et al., 2013). In contrast, the LI is inserted immediately
preceding the CBD and generates a clathrin machinery interac-
tion domain (Wollscheid et al., 2016). Notably, all four MYO6
splice variants (no insert, LI, SI, and LI+SI) occur in brain (Hei-
drych et al., 2009). We found that LI is necessary for the cLTD-
dependent increase in co-localization of MYO6 with a-adaptin
in PCs. Together, our data suggest that the myosin VI interaction
with the endocytic clathrin machinery is mechanistically impor-
tant for LTD in PCs.
The specific requirement of myosin VI for plasticity-related
AMPAR trafficking, but not for the regulation of synaptic AMPAR
levels during basal activity, might be due to the fact that CME is
required for activity-induced internalization of AMPARs (Man
et al., 2000;Wang and Linden, 2000), but not for their constitutive
endocytosis (Glebov et al., 2015). Together, our findings support
a model where myosin VI facilitates PF-PC LTD via driving CME
of AMPARs in PCs. Because myosin VI is regulated by calcium
(Batters et al., 2016), these results open up new possibilities of
how postsynaptic calcium signaling may induce PF-PC LTD.STAR+METHODS
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Antibodies
Rabbit anti-MYO6 (SP1295/1296) Wollscheid et al., 2016 N/A
Rabbit anti-MYO6 (clone H-215) Santa Cruz Cat#sc-50461; RRID: AB_2148617
Rabbit anti-MYO6 (clone KA15) Sigma-Aldrich Cat#M5187; RRID: AB_260563
Mouse anti-a-Tubulin (clone DM1A) Sigma-Aldrich Cat#T9026; RRID: AB_477593
Mouse anti-Calbindin-D-28K Sigma-Aldrich Cat#C9848; RRID: AB_476894
Rabbit anti-Calbindin-D-28K Merck Millipore Cat#AB1778; RRID: AB_2068336
Guinea pig anti-VGLUT1 Merck Millipore Cat#AB5905; RRID: AB_2301751
Guinea pig anti-VGLUT2 Merck Millipore Cat#AB2251-I; RRID: AB_2665454
Mouse monoclonal anti-Glutamate
Receptor 2, extracellular (clone 6C4)
Merck Millipore Cat#MAB397; RRID: AB_2113875
Mouse anti-a-Adaptin (clone 8) BD Biosciences Cat#610502; RRID: AB_397868
Mouse anti-a-Adaptin (clone AP6) Abcam Cat#ab2730; RRID: AB_303255
Rabbit anti-SAP97 Synaptic Systems Cat#124 302; RRID: AB_2092022
Mouse anti-GRIP1 (clone32/GRIP) BD Biosciences Cat#611319; RRID: AB_398845
Camelid anti-GFP nanobody (clone 1H1)
conjugated to Atto647N
Synaptic Systems/NanoTag
Biotechnologies
Cat#N0301-At647N; RRID: AB_2744620
Donkey anti-mouse peroxidase conjugated Jackson ImmunoResearch Cat#715-036-151; RRID: AB_2340774
Donkey anti-rabbit peroxidase conjugated Jackson ImmunoResearch Cat#711-036-152; RRID: AB_2340590
Donkey anti-rabbit Cy3 conjugated Jackson ImmunoResearch Cat#711-166-152; RRID: AB_2313568
Donkey anti-mouse Cy3 conjugated Jackson ImmunoResearch Cat#715-165-150; RRID: AB_2340813
Donkey anti-mouse Alexa Fluor 488 conjugated Jackson ImmunoResearch Cat#715-486-151; RRID: AB_2572300
Goat anti-mouse peroxidase-conjugated light
chain-specific
Jackson ImmunoResearch Cat#115-035-174; RRID: AB_2338512
Donkey anti-guinea pig Cy5 conjugated Jackson ImmunoResearch Cat#706-175-148; RRID: AB_2340462
Goat anti-mouse Alexa Fluor 594 conjugated BioLegend Cat#405326; RRID: AB_2563308
Chemicals, Peptides, and Recombinant Proteins
(S)-AMPA Tocris Cat#0254
D-AP5 Tocris Cat#0106
(+)-bicuculline Tocris Cat#0130
(-)-bicuculline methiodide Tocris Cat# 0131
Complete protease inhibitor tablets Sigma-Aldrich/Roche Cat#04693116001
(S)-3,5-DHPG Abcam Cat#ab120007
DNase I Sigma-Aldrich/Roche Cat#04716728001
Fetal bovine serum Thermo Fisher Scientific/GIBCO Cat#10082139
Papain Sigma-Aldrich Cat#P3125
Proteinase K Sigma-Aldrich/Roche Cat#03115828001
Taq DNA Polymerase Sigma-Aldrich/Roche Cat#04728874001
2,4,6-triiodophenol (TIP) Sigma-Aldrich Cat#19566
2,4,6-triiodophenol (TIP) Sigma-Aldrich Cat#137723
Tetrodotoxin citrate (TTX) Alomone Labs Cat#T-550
Triton X-100 Sigma-Aldrich/Roche Cat#11332481001
Critical Commercial Assays
Antigen Retrieval Reagent R&D Systems Cat#CTS013
Aqua-Poly/Mount Polysciences Cat#18606-20
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Dynabeads Protein G Thermo Fisher Scientific/Invitrogen Cat#10003D
Hibernate-E Thermo Fisher Scientific/GIBCO Cat#A1247601
Immobilon-P PVDF Membrane Merck Millipore Cat#IPVH00010
Immobilon HRP Substrate Merck Millipore Cat#WBKLS0500
Mouse Neuron Nucleofector Kit Lonza Cat# VPG-1001
QuickExtract Epicenter Cat#QE09050
Tissue-Tek O.C.T Compound Sakura Finetek Cat#4583
Experimental Models: Organisms/Strains
Mouse: B6 x STOCK Tyrc-ch
Bmp5se +/+ Myo6sv/J (Myo6sv/sv)
The Jackson Laboratory Stock No: 000578
Oligonucleotides
SV1: 50-CTGACCCTGATCACTTAGCAGAGTTG-30 This study N/A
SV2: 50-CATTGGGCCAGGTCACAGAAGTAAGC-30 This study N/A
SV3: 50-GGTCCTCTGAAAGAGTAACC-30 This study N/A
WW_M6FL_fw: 50-TGTACTACTAGTGAAGATGGA
AAGCCCGTTTGGGCACC-30
This study N/A
WW_M6STOP_rv: 50-TACACTGTCGACCTACTTG
AGCAGGTTCTGCAGCATGG-30
This study N/A
WW_SpeI_LNK_fw: 50-GCACTTAGATCTACTAG
TGGCCGGCCATAGACGCGTGTCGACTCATGG-30
This study N/A
Recombinant DNA
Plasmid: pL7-mGFP Wagner et al., 2011a N/A
Plasmid: pL7-mCherry Wagner et al., 2011a N/A
Plasmid: pL7-mGFP-F-tractin
(pL7-ITPKA-9-52–mGFP)
Wagner et al., 2011a N/A
Plasmid: pL7-FusionRed This study N/A
Plasmid: pFusionRed-C Evrogen Cat#FP411
Plasmid: pL7-mGFP-2 This study N/A
Plasmid: pL7-FusionRed-2 This study N/A
Plasmid: pL7-mGFP-Myo6-SI This study N/A
Plasmid: pL7-mGFP-Myo6-LI-SI This study N/A
Plasmid: pL7-mGFP-Myo6DCBD This study N/A
Plasmid: pL7-mGFP-actin This study N/A
Plasmid: pPA-TagRFP-actin Evrogen Cat#FP813
Plasmid: pCl-SEP-GluR1 Kopec et al., 2006 RRID: Addgene_24000
Plasmid: pCl-SEP-GluR2(R) Kopec et al., 2006 RRID: Addgene_24001
Plasmid: pL7-SEP-GluR1 This study N/A
Plasmid: pL7-SEP-GluR2 This study N/A
Software and Algorithms
Software: Clampfit 10.7 Molecular Devices https://www.moleculardevices.com
Software: Fiji Schindelin et al., 2012 http://fiji.sc
Software: Igor Pro WaveMetrics https://www.wavemetrics.com
Software: ImageJ 1.38 National Institutes of Health https://imagej.nih.gov
Software: MetaMorph 7.1 Molecular Devices https://www.moleculardevices.com
Software: Patchmaster HEKA http://www.heka.com
Software: Prism 7.04 GraphPad Software https://www.graphpad.com
Other
Glass bottom dish Invitro Scientific Cat#D35-14-1.5-N
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information can be obtained from and requests for reagents may be directed to and will be fulfilled by the Lead Contact,
Matthias Kneussel (matthias.kneussel@zmnh.uni-hamburg.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse lines and animal care
The study was carried out in accordance with the recommendations of the European Community Council Directive (2010/63/EU) in
accordance with German and EU laws, and the procedures used were approved by the City of Hamburg (Beho¨rde f€ur Gesundheit
und Verbraucherschutz, Lebensmittelsicherheit und Veterina¨rwesen). We used B6 x STOCK Tyrc-ch Bmp5se +/+ Myo6sv/J mice that
were obtained from The Jackson Laboratory (stock no. 000578) and that were repeatedly backcrossed to C57BL/6J WTmice, thereby
yieldingmice that lackTyrc-chandBmp5sealleles,butcarry theSnell’swaltzer (Myo6sv) allele that leads toaprematurestopcodon inMyo6
shortly after the myosin motor domain (Deol and Green, 1966; Avraham et al., 1995). HomozygousMyo6sv/sv (Snell’s waltzer), heterozy-
gousMyo6sv/+, and wild-type (WT;Myo6+/+) littermates were obtained by matingMyo6sv/+mice to each other. Genotypes were deter-
mined fromDNAobtained fromtail biopsies.Miceweremaintained inapathogen-free, temperature-andhumidity-controlledvivariumon
a12h light/dark schedule.Micehadaccess to standard laboratory chowandwater ad libitum. Bothmale and femalemicewere included
in the experiments. The age ofmicewas chosen in accordancewith the scientific question and is specified in theMethodDetails section.
Primary cell cultures
Primary dissociated cultures of neurons were prepared as described in Method Details and maintained in an incubator at 37C, with
5% CO2 and saturated humidity. Brains from pups of both sexes were used since Myo6
sv is an autosomal recessive allele that
disrupts Myo6 expression in both males and females.
METHOD DETAILS
DNA constructs
Prefix ‘pL7’ denotes plasmids carrying the PC-specific L7 (Pcp-2) promoter (Oberdick et al., 1990). Plasmids pL7-mGFP,
pL7-mCherry and pL7-mGFP-F-tractin (i.e., pL7-ITPKA-9-52–mGFP) were described previously (Wagner et al., 2011a; Wagner
et al., 2011b). To generate pL7-FusionRed for expressing a red fluorescent volume marker in PCs, the FusionRed ORF (Shemiakina
et al., 2012) was released from pFusionRed-C vector (#FP411, Evrogen, RU) using NheI, BglII restriction enzymes and ligatedwith the
vector backbone obtained by NheI, BglII digest of pL7-mGFP. A version of pL7-mGFP, termed pL7-mGFP-2, carrying a modified
multiple cloning site was created by replacing the 18 base pair (bp) BglII, SalI fragment in pL7-mGFP with a fragment generated
by BglII, SalI digestion of annealed oligonucleotides WW_SpeI_LNK_fw (50-GCACTTAGATCTACTAGTGGCCGGCCAT
AGACGCGTGTCGACTCATGG-30) and its reverse complement. Similarly, pL7-FusionRed-2 was generated by replacing the NcoI,
BglII fragment in pL7-mGFP-2 that contains mGFP with a fragment comprising FusionRed released from pL7-FusionRed via
NcoI, BglII digest. Plasmid pL7-mGFP-Myo6-SI encodes the full-length MYO6 splice isoform comprising the small insert (SI), fused
to the C terminus of mGFP. It carries a PCR-generated fragment corresponding to the Myo6 ORF of GenBank: NM_001039546.2,
amplified from mouse brain cDNA using oligonucleotide primers WW_M6FL_fw (50-TGTACTACTAGTGAAGATGGAAAGCC
CGTTTGGGCACC-30) and WW_M6STOP_rv (50-TACACTGTCGACCTACTTGAGCAGGTTCTGCAGCATGG-30). The PCR fragment
was digested with SpeI and SalI, and ligated with SpeI, SalI-digested pL7-mGFP-2 backbone. Plasmid pL7-mGFP-Myo6-LI-SI en-
codes theMYO6 splice isoform containing both large insert (LI) and SI. It carries theMyo6ORF as in GenBank: XM_006510835.3 and
corresponds to pL7-mGFP-Myo6-SI with a 227 bp DraIII, BssHII-fragment (harbors the LI insertion site) being replaced by a synthe-
sized 323 bp DraIII, BssHII-fragment containing LI (Eurofins, GER). To create a plasmid encodingMYO6 lacking the CBD, a SphI, SalI
fragment in pL7-mGFP-Myo6-SI was replaced by a synthesized SphI, SalI fragment encoding the C-terminal part of MYO6 without
the CBD (i.e., residues following amino acids VQATKAAAGT... being replaced by AAAPVRKLA-Stop). Plasmid pL7-mGFP-actin was
created by inserting a BglII, BamHI fragment encoding human b-actin from pPA-TagRFP-actin (#FP813, Evrogen, RU) in proper
orientation into the BglII-site of pL7-mGFP. To create pL7-SEP-GluA1, a fragment encoding SEP-tagged GluA1 was released
by NaeI, SalI digestion from pCI-SEP-GluR1 (gift from Robert Malinow; Addgene #24000; Kopec et al., 2006) and ligated with
NotI (blunted) and SalI-digested backbone of pL7 (Wagner et al., 2011b). Similarly, pL7-SEP-GluA2 was generated by ligating the
same digested pL7 backbone with a fragment encoding SEP-tagged GluA2 from pCI-SEP-GluR2(R) (gift from Robert Malinow;
Addgene #24001; Kopec et al., 2006) modified to encode GluA2- instead of GluA1-signal petide.
Genotyping
Genotypes were determined via PCR using genomic DNA obtained by digesting tissue biopsies with QuickExtract DNA Extraction
Solution (Epicenter) following the manufacturer’s instructions. Alternatively, biopsies were digested using Protease K lysis buffer
(10 mM Tris-HCl pH 8.5, 50 mM KCl, 2.5 mM EDTA, 0.45% [v/v] IPEGAL, 0.45% [v/v] Tween20, and 0.1 mg/ml Protease K
[#03115828001, Roche]) for 30 min at 65C, followed by incubation for 2 min at 97C. To discriminate between WT, homo- andCell Reports 28, 11–20.e1–e9, July 2, 2019 e3
heterozygous carriers of the Myo6sv allele, PCR was performed using primers SV1 (50-CTGACCCTGATCACTTAGCAGAGTTG-30),
SV2 (50-CATTGGGCCAGGTCACAGAAGTAAGC-30), and SV3 (50-GGTCCTCTGAAAGAGTAACC-30), Taq DNA Polymerase
(#04728874001, Roche), and reaction conditions of 94C for 2 min; 35 times (94C for 10 s, 54C for 30 s, 72C for 19 s); and
72C for 5 min. DNA fragments were separated on 0.8 – 1.5% agarose gels and imaged using a UV transillumination/digital camera
system (INTAS Science Imaging Instruments). The Myo6sv allele yields a 318 bp fragment, the WT allele yields a 230 bp fragment
(Figure S1A).
Neuronal cell culture
Dissociated cerebellar cultures
Preparation and transfection of dissociated cerebellar cultures containing Purkinje cells was done as described (Wagner et al., 2011b),
with minor modifications. Briefly, E17-18mouse embryos were obtained from pregnant C57BL/6JWTmice, or fromMyo6sv/+ females
mated toMyo6sv/+ males, after euthanization with CO2 and cervical dislocation. Embryonic brains were isolated in ice-cold modified
Hank’s balanced salt solution (MHS; GIBCO 14170088, Thermo Fisher Scientific) and were stored in Hibernate-E medium (GIBCO
A1247601, Thermo Fisher Scientific) for several hours while performing PCR genotyping on embryo head tissue DNA, if necessary.
The cerebellar primordium was minced and digested for 20 min at 30C using 7 U papain (P3125, Sigma-Aldrich). After addition of
heat-inactivated fetal bovine serum (FBS; GIBCO 10082139, Thermo Fisher Scientific), cells were triturated in MHS containing
12 mM MgSO4 (M2643, Sigma-Aldrich) and 5 U/ml DNase I (Roche 04716728001, Sigma-Aldrich) and filtered through a nylon
mesh (180 mm pore size, #NY8H04700, Millipore). After a wash in MHS, all cells from one cerebellum were nucleofected in a single
reaction using Mouse Neuron Nucleofector Kit (VPG-1001; Lonza, CH; nucleofection program O-003) according to the manufac-
turer’s protocol. Transfected cells from Myo6+/+ or Myo6sv/sv embryos were then mixed with untransfected cells from one WT cere-
bellum resuspended in 300 ml DFM [Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (D6434, Sigma-Aldrich) supple-
mented with 1x GlutaMAX (GIBCO 35050-038; Thermo Fisher Scientific), 100 mM putrescine dihydrochloride (P5780, Sigma-Aldrich),
30 nM Na2SeO3 (S5261, Sigma-Aldrich), 40 nM progesterone (P7556, Sigma-Aldrich), 0.77 nM L-3,3
0,5-tri-iodothyronine (T2877,
Sigma-Aldrich), 2 mM cytosine b-D-arabinofuranoside (C6645, Sigma-Aldrich), 200 mg/ml apo-transferrin (T1147, Sigma-Aldrich),
100 mg/ml BSA (A3156, Sigma-Aldrich), and 20 mg/ml insulin (I0516; Sigma-Aldrich)] containing 10% (v/v) FBS. The entire mixture
(cells from a transfected and an untransfected cerebellum) was plated into the well of a single glass bottom dish (D35-14-1.5-N, Invitro
Scientific) coated with poly-L-ornithine hydrobromide (P4638, Sigma-Aldrich). At 1.5 h after plating, 1.8 mL DFM containing 5 mg/ml
gentamicin (GIBCO 15710049; Thermo Fisher Scientific) were added per dish, and 4 - 36 h after plating 1.5 mL of culture medium
were replaced with fresh DFM/gentamicin. Subsequently 1 mL of medium was replaced by fresh DFM/gentamicin every week.
Cultured neurons were analyzed after 12-18 days in vitro (DIV).
Dissociated hippocampal cultures
Hippocampal neuron cultures were prepared from E17-18mouse embryos as described (Heisler et al., 2011) by seeding 80,000 cells
onto 12 mm coverslips coated with 5 mg/ml poly-L-lysine in phosphate-buffered saline (PBS). Before dissociation, embryonic brains
were stored in Hibernate-E medium (GIBCO A1247601, Thermo Fisher Scientific) for several hours while performing genotyping of
DNA obtained from embryo head tissue. Cells were cultured in Clonetics PNGM Primary Neuron Growth Medium (Lonza, CH) and
analyzed at 14 DIV.
Antibody application details
Primary antibodies
WB indicates dilution used for western blot, IHC indicates dilution used for immunohistochemistry, STED indicates dilution used for
STED, and IP indicates amount used per immunoprecipitation. aMYO6 (rabbit SP1295/SP1296; IHC 1:200; Wollscheid et al., 2016),
aMYO6 (rabbit, H-215, sc-50461, Santa Cruz; WB 1:200; antibody was pre-adsorbed against acetone powder prepared from Snell’s
waltzer brain and used 1:20 for IHC), aMYO6 (rabbit, KA15, M5187, Sigma-Aldrich, IP 4 mg), a-alpha-Tubulin (mouse, clone DM1A;
T9026; Sigma-Aldrich; WB 1:5,000), aCalbindin-D-28K (mouse, clone CB-955, C9848, Sigma-Aldrich; IHC 1:300), aCalbindin-D-28K
(rabbit, AB1778, Merck Millipore; IHC 1:100), aVGLUT1 (guinea pig, AB5905, Merck Millipore; IHC 1:5,000), aVGLUT2 (guinea pig,
AB2251, Merck Millipore; IHC 1:5,000), aGluA2 (mouse, clone 6C4, MAB397, Merck Millipore; WB 1:1,000), aalpha-adaptin (mouse,
clone 8, 610502, BD Biosciences, WB 1:1,000), aalpha-adaptin (mouse, clone AP6, ab2730, Abcam, STED, 1:200), aSAP97 (rabbit,
124302, Synaptic Systems, WB: 1:1,000), aGRIP1 (mouse, clone 32/GRIP, 611319, BD Biosciences, WB 1:1,000), and aGFP nano-
body conjugated to Atto647N (camelid, clone 1H1, N0301-At647N, Synaptic Systems/NanoTag Biotechnologies; STED, 1:200).
Secondary antibodies
Purchased from Jackson ImmunoResearch, if not indicated otherwise, and used at a dilution of 1:15,000 for WB, 1:500 for IHC,
and 1:200 for STED. a-mouse HRP (#715-036-151), a-rabbit HRP (#711-036-152), a-rabbit Cy3 (#711-166-152), a-mouse Cy3
(#715-165-150), a-mouse Alexa Fluor 488 (#715-486-151), a-guinea pig Cy5 (#706-176-148), and a-mouse Alexa Fluor 594
(405326, BioLegend).
Western blot of Myo6sv/sv cerebellar extracts
Cerebella of 4 - 7 month old mice were lysed in IMAC buffer (in mM: 20 HEPES, 100 potassium acetate, 40 KCl, 5 EGTA, 5 MgCl2,
pH 7.2) comprising 1% Triton X-100 and protease inhibitors (cOmplete tablets, Roche #04 693 116 001) by drawing into a 1 mLe4 Cell Reports 28, 11–20.e1–e9, July 2, 2019
syringe (5 x with 21G cannula, 8 x with 26G cannula). The homogenate was incubated on ice for 30 min before centrifugation for
5 min at 1,000 x g, 4C. The supernatant was mixed with 5 x SDS-loading buffer (10% SDS, 50% glycerol, 250 mM Tris pH 6.8,
500 mM DTT, 0.05% bromophenol blue), boiled (5 min, 95C), separated via SDS-PAGE using 10% gels, and blotted onto Immo-
bilon-P PVDF membranes (#IPVH00010, Merck Millipore). The indicated primary and suitable horse-radish peroxidase-coupled
secondary antibodies were used. Chemiluminiscence detection was performed using Immobilon Western HRP Substrate
(#WBKLS0500, Merck Millipore) and ChemoCam Imager ECL Typ HR 16-3200 (INTAS Science Imaging Instruments, Go¨ttingen,
Germany).
Co-IP assay with cerebellar slices
Cerebella of 22 - 24 week old adult mice (one cerebellum per IP sample) were dissected in ice-cold dissection buffer (in mM: 240
sucrose, 2.5 Na2HPO4, 2 MgSO4, 26 NaHCO3, 10 glucose, 1 CaCl2) and 400 mm thick cerebellar slices were prepared using a tissue
chopper (H. Saur, GER). Slices were allowed to recover for 1 h in chambers containing artificial cerebrospinal fluid (ACSF; in mM: 124
NaCl2, 5 KCl, 1.25 Na2HPO4, 2 MgSO4, 26 NaHCO3, 20 glucose, 2 CaCl2, bubbled with 5% CO2 and 95% O2, pH 7.4 at room tem-
perature [RT]). Slices were then left untreated (time point ‘‘Before’’) or treated for 15 min with ACSF containing 100 mM (S)-3,5-DHPG
(ab120007, Abcam) and 100 mM (S)-AMPA (#0254, Tocris) for cLTD induction. Treated slices were then transferred to regular ACSF
and allowed to recover for 15 (time point 30 min) and 45 min (time point 60 min). Subsequently, homogenization of cerebellar slices
was carried out with 26G and 20G cannulas in 500 ml homogenization buffer (in mM: 20 HEPES, 100 KCl, 5 EGTA, 5 MgCl2, pH 7.2)
containing 1% Triton X-100 and freshly added protease inhibitors (cOmplete tablets, Roche #04 693 116 001), 5 mM DTT and 1 mM
PMSF (Sigma-Aldrich). Homogenateswere incubated for 30min on ice followed by 5min centrifugation at 1,000 x g and supernatants
were collected for immunoprecipitation. Before, Dynabeads Protein G (Thermo Fisher Scientific/Invitrogen; 30 ml per sample) were
washed 3 times with PBS and incubated with 4 mg of the immunoprecipitation antibody (aMYO6, rabbit, clone KA15, M5187, Sigma-
Aldrich) in PBS overnight at 4C. Unbound antibody was removed by washing 3 times with homogenization buffer prior to incubation
with cerebellar slice homogenates on a rotation-wheel overnight at 4C. Beads were then washed 5 times for 5 min with IP buffer
(in mM: 50 NaCl, 50 Tris pH 7.5, 5 MgCl2) containing 1% Triton X-100 on a rotation-wheel. Samples were analyzed by SDS-PAGE
and western blotting using the indicated antibodies. Images were acquired using the ChemoCam Imager ECL Typ HR 16-3200
(INTAS Science Imaging Instruments, Go¨ttingen, Germany).
Immunolabeling of cerebellar sections
Immunoelectron microscopy
Adult mice were deeply anesthetized by a mixture of ketanest and rompun and transcardially perfused with 4% paraformaldehyde
(PFA) (w/v) and 0.1% glutaraldehyde (w/v) in phosphate buffer (PB). 150 mmvibratome sections of the brain were cut. After washing in
PBS pH 7.2, sections were treated with 0.3%H2O2 and 1%NaBH4 in PBS for 30 min to inhibit endogenous peroxidase activity. After
rinsing in PBS, sections were incubated with 10% horse serum (PS) containing 0.2% bovine serum albumin (BSA) for 15 min to block
nonspecific binding sites, and incubated with the specific aMYO6 (SP1295) antibody diluted 1:1,000 in PBS containing 1% PS and
0.2% BSA over night. Sections were washed with PBS, then incubated with biotinylated goat anti-rabbit IgG (Vector Laboratories,
CA) diluted 1:1,000 in carrier for 90 min. After rinsing, sections were incubated with ABC (Vector Laboratories, CA) diluted 1:100 in
PBS for 90 min. Sections were washed in PBS and reacted in diaminobenzidine (DAB)-H202 solution (Sigma-Aldrich) for 10 min. Sec-
tions were either mounted on glass coverslips for light microscopic observation or dehydrated and embedded after fixation with 1%
osmiumtetroxide (w/v) in Epon (Carl Roth GmbH & Co. KG, Germany). For postembedding immunogold labeling, small pieces of cry-
oprotected cerebellar tissue (2.3 M sucrose) were mounted on specimen holders immersed in liquid nitrogen and ultrathin sections
(70 nm) were cut and labeled according to Slot and Geuze (2007). Briefly, sections were collected on Carbon-Formvar-coated nickel
grids (Science Services GmbH, Germany). aMYO6 (SP1295) antibody was used diluted 1:100 and recognized with 10 nm large pro-
tein A gold secondary antibody (G. Posthuma, University Medical Center Utrecht). Ultrathin sections were examined in an EM902
(Zeiss, Germany). Pictures were taken with a TRS 2K digital camera (A. Tro¨ndle, Germany).Myo6sv/sv sections were used as negative
control.
Immunofluorescence microscopy
Adult mice (age 5 – 8 months) were transcardially perfused with 4% PFA in PBS. Brains were post-fixed in PFA/PBS (2 h),
cryoprotected overnight in PBS containing 30% sucrose. Then brains were frozen using Tissue-Tek O.C.T. Compound (Sakura
Finetek, Germany) on dry ice and sectioned into 25 mm thick sagittal sections using a cryostat. Sections were mounted on glass
slides and treated in 1 x Antigen Retrieval Reagent (R&D Systems #CTS013) for 4 min at 93C, cooled down for 10 min at RT,
rinsed in 0.1 M PB pH 7.3, and blocked in PB containing 5% normal donkey serum. Antibodies were diluted in PB containing 1%
normal donkey serum, 1% BSA, 0.1% Triton X-100 and sections were incubated for 2 days at 4C with gentle agitation. Sec-
tions were washed 3 times 10 min at RT with PB, incubated with fluorescently labeled secondary antibody in PB containing 1%
normal donkey serum, 1% BSA, 0.1% Triton X-100 for 24 h at 4C, washed 3 times 10 min at RT with PB, mounted on glass
slides with Aqua-Poly/Mount (Polysciences, Inc., USA), and imaged on a confocal laser scanning microscope (Olympus
FV1000; 60x objective; 488 nm, 559 nm, and 635 nm laser lines for excitation; Z stacks of planes with 1 mm optical thickness
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Purkinje cell live microscopy
General conditions
Cultured PCs were observed using a spinning disk confocal microscope (Visitron Systems) consisting of an inverted micro-
scope (Nikon Ti-E) equipped with a spinning disk (Yokogawa), solid state lasers (405, 488, 561 and 647 nm), a 100x objective,
an EM-CCD camera (Hamamatsu Photonics), autofocus system (Nikon TI-ND6-PFS), a multi-point FRAP/photo-activation
module (VisiFRAP, Visitron Systems), and an incubation chamber for controlled environmental conditions (37C, 5% CO2).
Cerebellar cultures were imaged directly in the culture dish containing their conditioned growth medium, if not indicated
otherwise.
SEP-GluA2 cLTD assay
For monitoring the effect of AMPA/DHPG on SEP-GluA2 fluorescence on PC spines (Figures 3F–3H), PCs transfected with pL7-SEP-
GluA2 and pL7-FusionRed were used. Medium was exchanged to Ringer solution (in mM: 135 NaCl, 5 KCl, 1 CaCl2, 2 MgCl2, 10
HEPES, 5 glucose, pH 7.4 with NaOH) immediately before starting the experiment. During observation, cultures were continuously
perfused at a flow rate of 0.5 ml/min at RT with Ringer, or for 15 min with Ringer containing 100 mM (S)-3,5-DHPG (ab120007, Ab-
cam) and 100 mM (S)-AMPA (#0254, Tocris), and (if indicated) 10 mM 2,4,6-triiodophenol (TIP; #19566, Sigma-Aldrich) or vehicle
(0.1% DMSO). SEP-GluA2 fluorescence was imaged every 5 min (1 s exposure time), 4 to 17 cells were followed simultaneously
in an experiment.
Fluorescence recovery after photobleaching
For measuring F-actin turnover in PC spines via fluorescence recovery after photobleaching (FRAP) analysis, cultured PCs trans-
fected with pL7-mGFP-actin and pL7-FusionRed were used. GFP-actin signal was imaged using spinning disk microscopy with a
frame rate of 1/sec (500 ms exposure time). In each trial, following 5 frames of baseline recording, GFP-actin signal was bleached
using 405 nm laser on 6 single spines of the same cell (circular region of 12 pixel diameter placed on each spine; total bleach
time 4 s). Imaging was resumed immediately thereafter for 145 s at 1 frame/sec. Similarly, FRAP analysis of SEP-GluA1 turnover
on the PC spine surface was performed using spinning disk microscopy of cultured PCs transfected with pL7-SEP-GluA1 and
pL7-FusionRed. To monitor both SEP-GluA1 and spines, green and red signals were imaged throughout the experiment. Exposure
times were 500 ms and 250 ms, respectively. Following 5 frames of baseline recording (5 s interval), the SEP-GluA1 signal was
bleached using 405 nm laser light on up to 6 single spines of one cell, as above. Imaging was resumed immediately thereafter at
0.4 frames/min.
Stimulated Emission Depletion (STED) imaging
For STED imaging, dissociated cerebellar cultures comprising PCs transfected with pL7-mGFP-Myo6-LI-SI or pL7-mGFP-Myo6-SI
were transferred to Ringer solution (control) or Ringer solution containing 100 mM (S)-3,5-DHPG (ab120007, Abcam) and 100 mM
(S)-AMPA (#0254, Tocris) for 15 min at RT for cLTD induction. Cultures were then transferred to fresh Ringer solution and allowed
to recover for 15 min before fixing with 4% PFA in PBS for 15 min at RT. Cells were then permeabilized and blocked for 20 min at
RT using PBS containing 0.23% Triton X-100 and 10% donkey serum. After that, cells were incubated for 1 h with aGFP nanobodies
conjugated to Atto647N and an antibody against a-adaptin (ab2730, Abcam, UK), followed by Alexa Fluor 594 secondary antibody.
Coverslips with stained cells were mounted with TDE Abberior Mounting Medium (Abberior Instruments GmbH, GER). 2D-STED im-
ages with a pixel size of 20 nm were acquired from the stained PCs with Abberior Instruments STED microscope (Abberior Instru-
ments GmbH, GER) using 60x P-Apo 1.4 NA oil objective. Atto 647Nwas excited by a 640 nm laser and depleted by a 775 nm pulsed
laser, Alexa Fluor 594 was excited by 561 nm laser and depleted by 775 nm pulsed laser.
GluA2 antibody uptake assay
Antibody recognizing the GluA2 N terminus (final concentration 10 mg/ml; MAB397, Merck Millipore) was added to culture medium
of live hippocampal neurons at 14 DIV. After incubation for 15 min at 37C, (S)-AMPA (final concentration 100 mM) or vehicle
(water) was added to the antibody-containing medium. After incubation for 10 min at 37C, cells were rinsed with PBS, followed
by fixation in 4% PFA/PBS for 10 min at RT. To visualize surface GluA2, the fixed cells were incubated with a-mouse Alexa Fluor
488 secondary antibody (1:200 in PBS with 1% BSA) for 1 h at RT. After that, cells were permeabilized for 8 min at RT using PBS
containing 0.25% Triton X-100 and incubated with a-mouse Cy3 secondary antibody (1:200 in PBS with 1% BSA) for 1 h at RT to
visualize internalized GluA2. Coverslips with stained cells were mounted with Aqua-Poly/Mount (Polysciences, USA) and imaged
on a confocal laser scanning microscope (Olympus FV1000, 60x objective, single plane acquired) using identical settings for
each cell.
Electrophysiology
Acute cerebellar slices
Acute cerebellar slices were prepared from 20 to 27 day-old mice as described previously (Groszer et al., 2008). Mice were decap-
itated under deep isoflurane anesthesia and cerebellar vermis was rapidly (< 1 min) removed and placed in ice-cold artificial cere-
brospinal fluid (ACSF2; in mM: 125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 20 glucose, bubbled with 95%e6 Cell Reports 28, 11–20.e1–e9, July 2, 2019
O2 and 5%CO2, pH 7.4 at RT). 300 mm thick parasagittal sliceswere cut (VT 1200 S, Leica, Germany) and incubated in ACSF2 at 35
C
for 40 min before they were stored at RT until use. Somatic whole-cell voltage-clamp recordings were obtained from visually iden-
tified PCs with an EPC-10 patch-clamp amplifier (HEKA, Germany), controlled by Patchmaster software (HEKA), and patch pipettes
pulled from borosilicate glass (Hilgenberg, Germany) to reach 4 - 6 MU resistance when filled with intracellular solution (in mM: 145
CsMeSO3, 4 NaCl, 10 HEPES, 10 TEA-Cl, 2 MgCl2, 4 Mg-ATP, 0.4 Na-GTP, 0.1 EGTA, pH 7.3 adjusted with HCl). Single EPSCs were
evoked at 0.1 Hz (baseline frequency) by activating PFs using a glass pipette placed in themolecular layer and stimuli (4 - 15 V, 100 ms)
applied through a stimulus isolator (npi electronic, Germany). For the LTD experiments shown in Figures 2B and 2C,WT andMyo6sv/sv
cerebellar slices were exposed to vehicle (0.01% DMSO) or 10 mM 2,4,6-triiodophenol (TIP; #19566, Sigma-Aldrich). To measure
paired-pulse facilitation of PF synapses (paired-pulse ratio) during these experiments, paired-pulse stimulation of PFswas performed
at 0.1 Hz (50 ms inter-stimulus interval; see Figures S2F–S2K). Wash in experiments were performed using 0.1% DMSO (vehicle) or
10 mM TIP (#137723, Sigma-Aldrich, Figures S2A–S2E). Series resistance (RS) compensation was adjusted so that the remaining,
uncompensated RS value was kept constant at 12 MU. Recordings were performed at RT in presence of 10 mM of GABAA-receptor
blocker (-)-bicuculline methiodide (#0131, Tocris). After obtaining a stable baseline for at least 10min, LTD of PF-EPSCswas induced
by pairing PF stimulationwith depolarizing voltage steps (to 0mV for 100ms; 90 times at 1Hz, synaptic stimulation in themiddle of the
depolarization; Crepel and Jaillard, 1991). Then, PF stimulation was resumed at 0.1 Hz and LTD induction was monitored for 60 min.
LTD was quantified as the average reduction of EPSC amplitudes at 50 to 60 min after LTD induction, normalized to the average
reduction during the 10 min before induction.
Dissociated cerebellar cultures
PCs in dissociated cerebellar culture transfected with pL7-mGFP and pL7-FusionRed were identified based on GFP-fluorescence
using a Zeiss Axiovert 405 M microscope. PCs were whole cell patch-clamped at 13 - 14 DIV at RT using borosilicate glass pipettes
(Hilgenberg, Germany). Pipettes had a resistance of 3 - 5 MU when filled with intracellular solution containing (in mM: 140 K+-gluco-
nate, 4 MgCl2, 0.5 EGTA, 10 HEPES, 4 Na2ATP, 0.4 Na3GTP, pH 7.3, adjusted with KOH). The extracellular solution corresponded to
Ringer containing (in mM) 0.0005 TTX (T-550, Alomone Labs), 0.020 (+)-bicuculline (#0130, Tocris), and 0.050 D-AP5 (#0106, Tocris),
pH 7.4, adjusted with NaOH. EPSCs were recorded at a holding potential of 70 mV with an EPC9 amplifier using Patchmaster
software (HEKA).
QUANTIFICATION AND STATISTICAL ANALYSIS
Western blot analysis
To quantify relative immunoblot signals for the co-IP assay, signal intensities of protein bands weremeasured using ImageJ software
(version 1.38, National Institutes of Health, NIH). Signal intensities were then normalized, as compared to loading control signals for
immunoblots and the mean of control data points was set to 1, in order to provide easier readability.
Microscopy image processing and analyses
Processing of shown images
Confocal laser scanning and STED microscopy: Linear contrast adjustment was applied to generate the shown images. Images
in Figure 1A are maximum intensity projections of four Z-planes, with images of the same channel subjected to identical
contrast adjustment. Images in Figures 1B and S1C–S1E are maximum intensity projections of three and four Z-planes, respec-
tively. Spinning disk confocal microscopy: Linear contrast adjustment and Gaussian or low-pass filters (to reduce noise)
were applied to generate the shown images. Images in Figures 3D and 3E were generated by averaging three consecutively
recorded images (5 s interval) to improve signal to noise ratio. Images shown in Figure S2M are Z stack maximum intensity
projections.
Spine enrichment quantification
The fold enrichment of GFP-tagged myosin (Figure 1E) and F-tractin (Figure S4B) in spines of live PCs was determined from spinning
diskmicroscopy images as follows, using Fiji image processing software (Schindelin et al., 2012): Integrated fluorescence intensity of
volume andGFPwasmeasured in a small circular region (constant dimension throughout analysis) placed either onto the spine head,
at the dendritic shaft nearby, or outside the cell (to measure background). Regions were placed using the volume image (i.e., blind to
the GFP signal). The respective background signals were subtracted from measured spine and dendrite intensities. To normalize for
volume effects and to calculate the relative enrichment of GFP-signal (e) in spines compared to dendrites, the following calculation
was performed with the background-corrected signals:
e=
GFPðSpineÞ x VolumeðDendriteÞ
GFPðDendriteÞ x Volume ðSpineÞ
8-10 spine/dendrite combinations were analyzed per cell to calculate the mean fold enrichment of GFP signal in spines.
PC dendrite length
Dendrite length was determined by manually tracing dendrites of cultured PCs expressing mGFP in Z stacks comprising the whole
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PC spine density
Spine density was determined from single plane spinning disk confocal images of dendrites of PCs expressing mGFP using Fiji
(analyzed mean dendrite length of 66 mm/cell).
SEP-GluA2 cLTD assay
The effect of AMPA/DHPG stimulation on SEP-GluA2 fluorescence on PC spines (Figures 3F–3H) was determined using Fiji by
applying a median filter (1 pixel wide) to the recorded images, followed by drawing regions around all visible spines (selected via
applying a threshold above dendrite background level). Total spine fluorescence intensity was measured and background intensity
subtracted. Post-induction SEP-GluA2 fluorescence (75min after start of the stimulation) was determined for each cell by normalizing
to initial SEP-GluA2 fluorescence (10 min before start of stimulation).
STED imaging
Image data were analyzed by selecting regions of interest on PCs, followed bymeasuring Pearson’s correlation coefficients between
two channels of the raw STED images via Coloc2 plug-in in Fiji.
FRAP analysis of GFP-actin
GFP-actin fluorescence intensity signal in bleached spines was quantified using Fiji (Schindelin et al., 2012). Intensity was measured
from a region of constant size encompassing the spine throughout the duration of the experiment. To determine recovery of the
bleached fluorescence signal, the intensity measured in each framewas first reduced by the intensity remaining in the first frame after
bleaching, yielding baseline-corrected intensity values Fb. To correct for overall bleaching during the experiment, Fb was multiplied
with a bleach factor (y) calculated for each trial and time point, yielding bleach-corrected intensity values (Fbc). To obtain y, fluores-
cence intensity in each frame was measured from part of the cell that included only spines not targeted by FRAP bleaching. After
background correction of the measured intensities, bleach factor y was determined for each time point using Excel (Microsoft) by
fitting a curve described by the exponential equation
y = atb
(a and b, fitted variables; t, time) to the values obtained by dividing the initial, background-corrected intensity by the background-
corrected intensity at each time point. Themean of Fbc (the bleach-corrected intensity values) before FRAPbleachingwas normalized
to 100% (F0), and Fbc values at each time point after bleaching were expressed relative to F0 (GFP-actin fluorescence, % of initial),
yielding the fluorescence recovery curve. For each experiment, a mean recovery curve was calculated by averaging the data of all
measured spines. Only experiments with > 10 FRAPed spines were considered. To calculate plateau and time constant of GFP-actin
fluorescence intensity recovery in spines, the mean recovery curves were fitted to the equation
y =Pð1 expðkxÞÞ
(y, GFP-actin fluorescence intensity; x, time; P, plateau; k, inverse of t).
FRAP analysis of SEP-GluA1
SEP signal recovery was only analyzed if presence of the spine was confirmed during the experiment by FusionRed signal. SEP fluo-
rescence intensity of single spines was measured using Fiji before and after bleaching from a region comprising the SEP signal of a
single spine and defined by thresholding the image at background level. Similar as for FRAP analysis of GFP-actin, the recovery of
fluorescence intensity was determined by subtracting the intensity measured in the first frame after bleaching from the intensity
measured in each frame, yielding Fb. The mean Fb of the first 5 frames was normalized to 100% (F0), and Fb at each time point
following bleaching was expressed relative to F0. To calculate plateau and time constant of SEP fluorescence intensity recovery
in spines, the mean recovery curves were fitted to the equation
y =Pð1 expðkxÞÞ
(y, GFP-actin fluorescence intensity; x, time; P, plateau; k, inverse of t).
GluA2 antibody uptake assay
To determine the GluA2 internalization index, signal intensities of surface and internalized GluA2 were measured along neurites of
randomly chosen hippocampal neurons using Fiji. The internalization index was determined via dividing the background-corrected
internalized GluA2 mean intensity by the background-corrected surface GluA2 mean intensity.
Electrophysiology data analyses
Acute cerebellar slices
Recordings were analyzed using Igor Pro (WaveMetrics). Slices were excluded if a sudden change in series resistance, holding
current or synaptic responses occurred.
Dissociated cerebellar cultures
mEPSCs were analyzed with Clampfit 10.7 (Molecular Devices). A template was constructed to detect and determine the amplitude
of mEPSCs. 100 mEPSCs were collected in each PC after visual confirmation of each mEPSC. Only those PCs were analyzed
which exhibited a healthy appearance and presented vivid synaptic activity in the beginning of an experiment, while recording in
extracellular solution not yet containing TTX, D-AP5 and bicuculline.e8 Cell Reports 28, 11–20.e1–e9, July 2, 2019
Statistical analyses
Raw values were imported into Excel (Microsoft) before statistic analyses were performed using Prism 7.04 (GraphPad Software,
Inc.). The exact value of n is stated in the figure legends, in case it is not directly visible from the shown graph. Statistical tests
used, what n represents, and whether mean, median, SD, SEM, confidence intervals are shown, is indicated in the figure legends.
For datasets fulfilling the Shapiro-Wilk normality test, P values were obtained using unpaired and two-sided Student’s t test (if vari-
ance in datasets was the same according to F test) or using t test with Welch’s correction (if variance in datasets was different
according to F test). When comparing two groups not fulfilling the normality test, exact P values were obtained using Mann-Whitney
test. For comparison of more than two groups that all fulfill the normality test, presence of a significant difference was first evaluated
using ordinary one-way ANOVA, followed byDunnett’s, Sidak‘s or Tukey’smultiplemultiple comparisons test, as indicated. For com-
parison of more than two groups where not all fulfill the normality test, presence of a significant difference was first evaluated
using ordinary Kruskal-Wallis test, followed by Dunn’s multiple comparisons test. Significance values are indicated in the figures
as * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; p > 0.05 was deemed not significant (n.s.).Cell Reports 28, 11–20.e1–e9, July 2, 2019 e9
